ABSTRACT
SARS-CoV-2 infection in hospital areas is of a particular concern, since the close interaction between health care personnel and patients diagnosed with COVID-19, which allows virus to be easily spread between them and subsequently to their families and communities. Preventing SARS-CoV-2 infection among healthcare personnel is essential to reduce the frequency of infections and outbreaks during the pandemic considering that they work in high-risk areas. In this research, silver nanoparticles (AgNPs) were tested in vitro and shown to have an inhibitory effect on SARS-CoV-2 infection in cultured cells. Subsequently, we assess the effects of mouthwash and nose rinse with ARGOVIT® silver nanoparticles (AgNPs), in the prevention of SARS-CoV-2 contagion in health workers consider as high-risk group of acquiring the infection in the General Tijuana Hospital, Mexico, a hospital for the exclusive recruitment of patients diagnosed with COVID-19. We present a prospective randomized study of 231 participants that was carried out for 9 weeks (during the declaration of a pandemic). The "experimental" group was instructed to do mouthwash and nose rinse with the AgNPs solution; the "control" group was instructed to do mouthwashes and nose rinse in a conventional way. The incidence of SARS-CoV-2 infection was significantly lower in the "experimental" group (two participants of 114, 1.8%) compared to the "control" group (thirty-three participants of 117, 28.2%), with an 84.8% efficiency. We conclude that the mouth and nasal rinse with AgNPs helps in the prevention of SARS-CoV-2 infection in health personnel who are exposed to patients diagnosed with COVID-19.
Subject(s)
COVID-19/prevention & control , Health Personnel , Metal Nanoparticles/administration & dosage , Mouthwashes/administration & dosage , SARS-CoV-2 , Silver/administration & dosage , Adolescent , Adult , Aged , Animals , COVID-19/epidemiology , Chlorocebus aethiops , Female , Humans , Male , Mexico , Middle Aged , Vero CellsABSTRACT
STUDY OBJECTIVE: Chemical pleurodesis may be the best available treatment for recurrent and troublesome pleural effusions when the underlying cause cannot be corrected. A wide variety of pleural irritants have been used, but the search for the ideal agent for pleurodesis continues. The purpose of our study is to evaluate the efficacy and safety of iodopovidone as an agent for pleurodesis in patients with recurrent pleural effusion. DESIGN AND SETTING: Multicenter prospective study. INTERVENTION: The pleurodesis solution consisted of a mixture of 20 mL 10% iodopovidone and 80 mL normal saline solution. It was infused and left in the pleural cavity for 2 h. In 12 patients, pleurodesis was performed through a tube thoracostomy, and in the remaining 40 patients it was carried out at the end of diagnostic thoracoscopy. RESULTS: Fifty-two patients were included, with a mean (+/- SEM) age of 56.6 +/- 1.84 years. Eighty-five percent of the cases were related to a malignant neoplasm. A complete response, with no reaccumulation of fluid during follow-up, was obtained in 50 patients (96.1%). A second procedure was successful in the two remaining patients. Three patients (5.8%) experienced intense pleuritic pain and systemic hypotension after the instillation of the sclerosing agent. They recovered without incident. The mean length of follow-up was 13 +/- 1.46 months, with a median of 8.5 months. There were no 30-day postoperative deaths. CONCLUSIONS: Iodopovidone is an effective, safe, readily available, and inexpensive alternative to achieve chemical pleurodesis in cases of recurrent, incapacitating effusions, regardless of etiology.
Subject(s)
Anti-Infective Agents, Local/administration & dosage , Pleural Effusion/therapy , Pleurodesis , Povidone-Iodine/administration & dosage , Chest Tubes , Follow-Up Studies , Humans , Prospective Studies , Recurrence , Time FactorsABSTRACT
El presente artículo expone un caso de neumocitoma exclerosante del pulmón, en un varón de 29 años de edad, que se manifestó como una masa solitaria en una radiografía rutinaria del tórax. La tomografía computada corroboró que se trataba de una neoplasia sólida, pero no se identificaron hallazgos que puedieran sugerir la etiología específica del tumor. La biopsia por aspiración con aguja delgada no fue diagnóstica. El tumor fue enucleado por toracotomía; reveló las características histológicas típicas del neumocitoma esclerosante. Se presenta una revisión de la literatura sobre los aspectos clínicos e histopatológicos del neumocitoma esclerosante, y se discuten modificaciones reciente en el concepto histopatológico de esta neoplasia. Se ha considerado, por algunos autores que esta neoplasia presenta un potencial de malignización
Subject(s)
Humans , Male , Adult , Biopsy, Needle/instrumentation , Hemangioma/classification , Hemangioma/pathology , Lung Neoplasms , Lung Neoplasms/diagnosis , Radiography, Thoracic , Tomography, X-Ray Computed/methodsABSTRACT
El linfoma no-Hodgkin pleural primario, no asociado al síndrome de inmunodeficiencia adquirida, es una entidad extremadamente rara. Esta neoplasia parece estar consistentemente asociada a historia de patología pleural y a una infección crónica de las células B, por el virus de Epstein-Barr. Se ha postulado que la inflamación crónica propicia la evolución clonal de células B infectadas por este virus. Presentamos un caso de linfoma pleural primario en un sujeto no inmunocomprometido, que se presentó inicialmente como un derrame pleural